Loading…
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with pre...
Saved in:
Published in: | BMC cancer 2019-05, Vol.19 (1), p.487-487, Article 487 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553 |
---|---|
cites | cdi_FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553 |
container_end_page | 487 |
container_issue | 1 |
container_start_page | 487 |
container_title | BMC cancer |
container_volume | 19 |
creator | Werutsky, Gustavo Maluf, Fernando Cotait Cronemberger, Eduardo Henrique Carrera Souza, Vinicius Dos Santos Martins, Suelen Patricia Peixoto, Fábio Smaletz, Oren Schutz, Fábio Herchenhorn, Daniel Santos, Telma Mavignier Carcano, Flavio Queiroz Muniz, David Nunes Filho, Paulo R S Zaffaroni, Facundo Barrios, Carlos Fay, André |
description | Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.
Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded.
There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy.
This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020. |
doi_str_mv | 10.1186/s12885-019-5709-y |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cc80e2d601e94b1baf2980625067c4c9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A586921520</galeid><doaj_id>oai_doaj_org_article_cc80e2d601e94b1baf2980625067c4c9</doaj_id><sourcerecordid>A586921520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553</originalsourceid><addsrcrecordid>eNp1k1Fv0zAQxyMEYmPwAXhBlpAQPGTYThwnPCBVBUalSpOgPFsX22k9pXFnO4V9RT4V13WMFoHyEPv8-_8vufNl2XNGzxmrq7eR8boWOWVNLiRt8psH2SkrJct5SeXDg_VJ9iTGK0qZrGn9ODspGOOcM36a_VysLJlPppcXOS2ZIJsVREtmM5KCg_4dgdYFSDb4wRLQNuGawGDI5MOCbG2IYySwgX5MsHbG3of-ozpE3UA2kJwdUiTfXVoRMFsYtDVkE3y8lejdPuxPBz_kGmJCX-cHkmxMSO1T9HZr-_g0e9RBH-2zu_dZ9u3Tx8X0cz6_vJhNJ_NcV1ykXNqmFK0QoulE1TSSGSPbxtQlN7KkXApBm4pLqqUAjWTb1WXFKlYb2wETojjLZntf4-FKbYJbQ7hRHpy6DfiwVBCS071VWtfUclNRhklb1kLHm5riZ9BK6lI36PV-77UZ27U1GqsRoD8yPT4Z3Eot_VZVoihkwdDg9Z1B8NcjFkWtXdS272GwfoyK8wL7LAXdoS__Qq_8GAYsFVJlwUXNRfOHWgL-gBs6j3n1zlRNRF01nAlOkTr_B4WPsWunsSedw_iR4M2RAJlkf6QljDGq2dcvx-yrA3ZloU-r6PHiYOPjMcj2oMYbE4Pt7gvHqNpNiNpPiMIJUbsJUTeoeXFY8XvF75EofgFZKAu5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243258259</pqid></control><display><type>article</type><title>The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels</title><source>PubMed Central Free</source><source>ProQuest Publicly Available Content database</source><creator>Werutsky, Gustavo ; Maluf, Fernando Cotait ; Cronemberger, Eduardo Henrique ; Carrera Souza, Vinicius ; Dos Santos Martins, Suelen Patricia ; Peixoto, Fábio ; Smaletz, Oren ; Schutz, Fábio ; Herchenhorn, Daniel ; Santos, Telma ; Mavignier Carcano, Flavio ; Queiroz Muniz, David ; Nunes Filho, Paulo R S ; Zaffaroni, Facundo ; Barrios, Carlos ; Fay, André</creator><creatorcontrib>Werutsky, Gustavo ; Maluf, Fernando Cotait ; Cronemberger, Eduardo Henrique ; Carrera Souza, Vinicius ; Dos Santos Martins, Suelen Patricia ; Peixoto, Fábio ; Smaletz, Oren ; Schutz, Fábio ; Herchenhorn, Daniel ; Santos, Telma ; Mavignier Carcano, Flavio ; Queiroz Muniz, David ; Nunes Filho, Paulo R S ; Zaffaroni, Facundo ; Barrios, Carlos ; Fay, André</creatorcontrib><description>Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.
Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded.
There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy.
This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-019-5709-y</identifier><identifier>PMID: 31122212</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject><![CDATA[Abiraterone ; Abiraterone Acetate - administration & dosage ; Abiraterone Acetate - therapeutic use ; Acetic acid ; Adenocarcinoma ; Adenocarcinoma - drug therapy ; Analysis ; Androgen deprivation therapy ; Androgen Receptor Antagonists - administration & dosage ; Androgen Receptor Antagonists - therapeutic use ; Androgens ; Antigens ; Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Apalutamide ; Biochemistry ; Cancer metastasis ; Cancer patients ; Cancer therapies ; Cardiovascular diseases ; Castration ; Castration-sensitive prostate cancer ; Chemotherapy ; Clinical trials ; Comparative analysis ; Disease-Free Survival ; Dosage and administration ; Drug therapy ; Endocrine therapy ; Enzalutamide ; Glucocorticoids ; Goserelin ; Goserelin - administration & dosage ; Goserelin - therapeutic use ; Hormonal therapy ; Humans ; Male ; Metastases ; Metastasis ; Osteoporosis ; Patient Reported Outcome Measures ; Patients ; Prednisone ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Prostate cancer ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Quality of Life ; Radiation therapy ; Recurrence (Disease) ; Response rates ; Sexual disorders ; Side effects ; Study Protocol ; Testosterone ; Testosterone - blood ; Thiohydantoins - administration & dosage ; Thiohydantoins - therapeutic use ; Treatment Outcome]]></subject><ispartof>BMC cancer, 2019-05, Vol.19 (1), p.487-487, Article 487</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553</citedby><cites>FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533731/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2243258259?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31122212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Werutsky, Gustavo</creatorcontrib><creatorcontrib>Maluf, Fernando Cotait</creatorcontrib><creatorcontrib>Cronemberger, Eduardo Henrique</creatorcontrib><creatorcontrib>Carrera Souza, Vinicius</creatorcontrib><creatorcontrib>Dos Santos Martins, Suelen Patricia</creatorcontrib><creatorcontrib>Peixoto, Fábio</creatorcontrib><creatorcontrib>Smaletz, Oren</creatorcontrib><creatorcontrib>Schutz, Fábio</creatorcontrib><creatorcontrib>Herchenhorn, Daniel</creatorcontrib><creatorcontrib>Santos, Telma</creatorcontrib><creatorcontrib>Mavignier Carcano, Flavio</creatorcontrib><creatorcontrib>Queiroz Muniz, David</creatorcontrib><creatorcontrib>Nunes Filho, Paulo R S</creatorcontrib><creatorcontrib>Zaffaroni, Facundo</creatorcontrib><creatorcontrib>Barrios, Carlos</creatorcontrib><creatorcontrib>Fay, André</creatorcontrib><title>The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.
Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded.
There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy.
This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.</description><subject>Abiraterone</subject><subject>Abiraterone Acetate - administration & dosage</subject><subject>Abiraterone Acetate - therapeutic use</subject><subject>Acetic acid</subject><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - drug therapy</subject><subject>Analysis</subject><subject>Androgen deprivation therapy</subject><subject>Androgen Receptor Antagonists - administration & dosage</subject><subject>Androgen Receptor Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Antigens</subject><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Apalutamide</subject><subject>Biochemistry</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Cardiovascular diseases</subject><subject>Castration</subject><subject>Castration-sensitive prostate cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Disease-Free Survival</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Endocrine therapy</subject><subject>Enzalutamide</subject><subject>Glucocorticoids</subject><subject>Goserelin</subject><subject>Goserelin - administration & dosage</subject><subject>Goserelin - therapeutic use</subject><subject>Hormonal therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Osteoporosis</subject><subject>Patient Reported Outcome Measures</subject><subject>Patients</subject><subject>Prednisone</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Quality of Life</subject><subject>Radiation therapy</subject><subject>Recurrence (Disease)</subject><subject>Response rates</subject><subject>Sexual disorders</subject><subject>Side effects</subject><subject>Study Protocol</subject><subject>Testosterone</subject><subject>Testosterone - blood</subject><subject>Thiohydantoins - administration & dosage</subject><subject>Thiohydantoins - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1k1Fv0zAQxyMEYmPwAXhBlpAQPGTYThwnPCBVBUalSpOgPFsX22k9pXFnO4V9RT4V13WMFoHyEPv8-_8vufNl2XNGzxmrq7eR8boWOWVNLiRt8psH2SkrJct5SeXDg_VJ9iTGK0qZrGn9ODspGOOcM36a_VysLJlPppcXOS2ZIJsVREtmM5KCg_4dgdYFSDb4wRLQNuGawGDI5MOCbG2IYySwgX5MsHbG3of-ozpE3UA2kJwdUiTfXVoRMFsYtDVkE3y8lejdPuxPBz_kGmJCX-cHkmxMSO1T9HZr-_g0e9RBH-2zu_dZ9u3Tx8X0cz6_vJhNJ_NcV1ykXNqmFK0QoulE1TSSGSPbxtQlN7KkXApBm4pLqqUAjWTb1WXFKlYb2wETojjLZntf4-FKbYJbQ7hRHpy6DfiwVBCS071VWtfUclNRhklb1kLHm5riZ9BK6lI36PV-77UZ27U1GqsRoD8yPT4Z3Eot_VZVoihkwdDg9Z1B8NcjFkWtXdS272GwfoyK8wL7LAXdoS__Qq_8GAYsFVJlwUXNRfOHWgL-gBs6j3n1zlRNRF01nAlOkTr_B4WPsWunsSedw_iR4M2RAJlkf6QljDGq2dcvx-yrA3ZloU-r6PHiYOPjMcj2oMYbE4Pt7gvHqNpNiNpPiMIJUbsJUTeoeXFY8XvF75EofgFZKAu5</recordid><startdate>20190523</startdate><enddate>20190523</enddate><creator>Werutsky, Gustavo</creator><creator>Maluf, Fernando Cotait</creator><creator>Cronemberger, Eduardo Henrique</creator><creator>Carrera Souza, Vinicius</creator><creator>Dos Santos Martins, Suelen Patricia</creator><creator>Peixoto, Fábio</creator><creator>Smaletz, Oren</creator><creator>Schutz, Fábio</creator><creator>Herchenhorn, Daniel</creator><creator>Santos, Telma</creator><creator>Mavignier Carcano, Flavio</creator><creator>Queiroz Muniz, David</creator><creator>Nunes Filho, Paulo R S</creator><creator>Zaffaroni, Facundo</creator><creator>Barrios, Carlos</creator><creator>Fay, André</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190523</creationdate><title>The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels</title><author>Werutsky, Gustavo ; Maluf, Fernando Cotait ; Cronemberger, Eduardo Henrique ; Carrera Souza, Vinicius ; Dos Santos Martins, Suelen Patricia ; Peixoto, Fábio ; Smaletz, Oren ; Schutz, Fábio ; Herchenhorn, Daniel ; Santos, Telma ; Mavignier Carcano, Flavio ; Queiroz Muniz, David ; Nunes Filho, Paulo R S ; Zaffaroni, Facundo ; Barrios, Carlos ; Fay, André</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Abiraterone</topic><topic>Abiraterone Acetate - administration & dosage</topic><topic>Abiraterone Acetate - therapeutic use</topic><topic>Acetic acid</topic><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - drug therapy</topic><topic>Analysis</topic><topic>Androgen deprivation therapy</topic><topic>Androgen Receptor Antagonists - administration & dosage</topic><topic>Androgen Receptor Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Antigens</topic><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Apalutamide</topic><topic>Biochemistry</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Cardiovascular diseases</topic><topic>Castration</topic><topic>Castration-sensitive prostate cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Disease-Free Survival</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Endocrine therapy</topic><topic>Enzalutamide</topic><topic>Glucocorticoids</topic><topic>Goserelin</topic><topic>Goserelin - administration & dosage</topic><topic>Goserelin - therapeutic use</topic><topic>Hormonal therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Osteoporosis</topic><topic>Patient Reported Outcome Measures</topic><topic>Patients</topic><topic>Prednisone</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Quality of Life</topic><topic>Radiation therapy</topic><topic>Recurrence (Disease)</topic><topic>Response rates</topic><topic>Sexual disorders</topic><topic>Side effects</topic><topic>Study Protocol</topic><topic>Testosterone</topic><topic>Testosterone - blood</topic><topic>Thiohydantoins - administration & dosage</topic><topic>Thiohydantoins - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Werutsky, Gustavo</creatorcontrib><creatorcontrib>Maluf, Fernando Cotait</creatorcontrib><creatorcontrib>Cronemberger, Eduardo Henrique</creatorcontrib><creatorcontrib>Carrera Souza, Vinicius</creatorcontrib><creatorcontrib>Dos Santos Martins, Suelen Patricia</creatorcontrib><creatorcontrib>Peixoto, Fábio</creatorcontrib><creatorcontrib>Smaletz, Oren</creatorcontrib><creatorcontrib>Schutz, Fábio</creatorcontrib><creatorcontrib>Herchenhorn, Daniel</creatorcontrib><creatorcontrib>Santos, Telma</creatorcontrib><creatorcontrib>Mavignier Carcano, Flavio</creatorcontrib><creatorcontrib>Queiroz Muniz, David</creatorcontrib><creatorcontrib>Nunes Filho, Paulo R S</creatorcontrib><creatorcontrib>Zaffaroni, Facundo</creatorcontrib><creatorcontrib>Barrios, Carlos</creatorcontrib><creatorcontrib>Fay, André</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Werutsky, Gustavo</au><au>Maluf, Fernando Cotait</au><au>Cronemberger, Eduardo Henrique</au><au>Carrera Souza, Vinicius</au><au>Dos Santos Martins, Suelen Patricia</au><au>Peixoto, Fábio</au><au>Smaletz, Oren</au><au>Schutz, Fábio</au><au>Herchenhorn, Daniel</au><au>Santos, Telma</au><au>Mavignier Carcano, Flavio</au><au>Queiroz Muniz, David</au><au>Nunes Filho, Paulo R S</au><au>Zaffaroni, Facundo</au><au>Barrios, Carlos</au><au>Fay, André</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2019-05-23</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>487</spage><epage>487</epage><pages>487-487</pages><artnum>487</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.
Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded.
There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy.
This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31122212</pmid><doi>10.1186/s12885-019-5709-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2407 |
ispartof | BMC cancer, 2019-05, Vol.19 (1), p.487-487, Article 487 |
issn | 1471-2407 1471-2407 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_cc80e2d601e94b1baf2980625067c4c9 |
source | PubMed Central Free; ProQuest Publicly Available Content database |
subjects | Abiraterone Abiraterone Acetate - administration & dosage Abiraterone Acetate - therapeutic use Acetic acid Adenocarcinoma Adenocarcinoma - drug therapy Analysis Androgen deprivation therapy Androgen Receptor Antagonists - administration & dosage Androgen Receptor Antagonists - therapeutic use Androgens Antigens Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols Apalutamide Biochemistry Cancer metastasis Cancer patients Cancer therapies Cardiovascular diseases Castration Castration-sensitive prostate cancer Chemotherapy Clinical trials Comparative analysis Disease-Free Survival Dosage and administration Drug therapy Endocrine therapy Enzalutamide Glucocorticoids Goserelin Goserelin - administration & dosage Goserelin - therapeutic use Hormonal therapy Humans Male Metastases Metastasis Osteoporosis Patient Reported Outcome Measures Patients Prednisone Prednisone - administration & dosage Prednisone - therapeutic use Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Quality of Life Radiation therapy Recurrence (Disease) Response rates Sexual disorders Side effects Study Protocol Testosterone Testosterone - blood Thiohydantoins - administration & dosage Thiohydantoins - therapeutic use Treatment Outcome |
title | The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A29%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20LACOG-0415%20phase%20II%20trial:%20abiraterone%20acetate%20and%20ADT%20versus%20apalutamide%20versus%20abiraterone%20acetate%20and%20apalutamide%20in%20patients%20with%20advanced%20prostate%20cancer%20with%20non-castration%20testosterone%20levels&rft.jtitle=BMC%20cancer&rft.au=Werutsky,%20Gustavo&rft.date=2019-05-23&rft.volume=19&rft.issue=1&rft.spage=487&rft.epage=487&rft.pages=487-487&rft.artnum=487&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-019-5709-y&rft_dat=%3Cgale_doaj_%3EA586921520%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-7e945b5559f569971dd7b9d842d7402755096270c75ac45bbf8461618defa1553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2243258259&rft_id=info:pmid/31122212&rft_galeid=A586921520&rfr_iscdi=true |